Table 2.

Clinical trials investigating Baricitinib in treatment of COVID-19.

Clinical trial identifier	Status	Study design	No of enrolled	Age(y)	Treatment	Outcomes
NCT04401579	Completed	double-blind, randomized, placebo-controlled trial (ACTT-2)	1033	18–99	Baricitinib (4 mg/d) + RDV vs. Placebo + RDV	Time to recovery
NCT04390464	Recruiting	Randomized, parallel arm, open-label (TACTIC-R)	1167	18 ∼	Baricitinib (4 mg/d) + SOC vs. Ravulizumab + SOC	Time to the incidence of the composite endpoint of: death, mechanical ventilation, cardiovascular organ
NCT04358614	Completed	Interventional	12	12–85	Baricitinib-4 mg/d	To assess the safety of Baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.
NCT04362943	Completed	Retrospective, observational, single-center cohort study	576	70∼	Baricitinib vs. Anakinra	All-cause mortality
NCT04346147	Active, not recruiting	Randomized, single-center, parallel assignment, open-label	168	18∼	Hydroxychloroquine + one of: Baricitinib (4 mg/d × 7 days) or Lopinavir/ritonavir or Imatinib	Time to clinical improvement on 7-point ordinal scale
NCT04320277	Not yet recruiting	Non randomized, before-after, single-center	200	18∼	Baricitinib (4 mg/d x14 days) + antiviral vs. antiviral and/or hydroxychloroquine	ICU transfer
NCT04373044	Terminated	Prospective, single-arm, two center, open label	6	18∼	Baricitinib (4 mg/d × 14 days) + one of: Hydroxychloroquine or Lopinavir/ritonavir/Remdesivir	Death or mechanical ventilation at day 14
NCT04321993	Recruiting	Non randomized, multi-center, parallel assignment, open label	800	18∼	Baricitinib (2 mg/d x10 days) vs. SOC	Clinical improvement on 7-point ordinal scale at day 15
NCT04421027	Completed	Randomized, double-Blind, placebo controlled, parallel assignment, interventional (COV-BARRIER)	1585	18∼	Baricitinib-4 mg/d vs. placebo	Cases needing: non-invasive ventilation, high-flow oxygen, invasive mechanical ventilation
NCT04393051	Not yet recruiting	Randomized, multicentered, open-label, parallel assignment, interventional	126	18∼	Baricitinib- 4 mg or 2 mg/d for 14 days. vs. SOC	The decrease in patients requiring invasive ventilation
NCT04399798	Not yet recruiting	Single group, assignment, open-label, interventional	13	18–74	Baricitinib-4 mg/d for 7 days	Response to treatment: absence of moderate to severe oxygenation impairment
NCT04365764	Recruiting	Cross sectional, case control, observational	400	no limit	Treatment including Baricitinib vs. patients are not given treatment.	Composite of death and mechanical ventilation.
NCT04366206	Recruiting	Prospective, cohort, observational	143	no limit	Treatment including Baricitinib vs. patients are not exposed to treatment or risk factor	Composite of death and mechanical ventilation
NCT04970719	Recruiting	Interventional, randomized, parallel, assignment	382	18∼	Baricitinib vs. Dexamethasone vs. Remdesivir	Rescue treatment
NCT04640168	Active, not recruiting	Randomized, parallel assignment, interventional (ACTT-4)	1010	18–99	Baricitinib Dexamethasone Placebo Remdesivir	The proportion of subjects not meeting criteria for one of the following two ordinal scale categories at any time: death; hospitalized, on invasive mechanical ventilation or ECMO
NCT04381936	Recruiting	Randomized, controlled, open-label platform trial (RECOVER)	8156	no limit	Baricitinib 4 mg/d for 10 days vs. UC	28-day mortality

VDR = remdesivir; SOC = standard of care; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation.